CLOs on the Move

Repligen Corp

www.repligen.com

 
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.repligen.com
  • 41 Seyon St Ste 100
    Waltham, MA USA 02453
  • Phone: 781.250.0111

Executives

Name Title Contact Details
Amanda Fulton
Sr. Director and Associate General Counsel Profile
Squire Servance
Senior Vice President, General Counsel and Corporate Secretary Profile

Similar Companies

Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.

TransMolecular

TransMolecular, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

BELPORT COMPANY INC

BELPORT COMPANY INC is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutripro Biosystems

Nutripro Biosystems, Inc is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.